Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.

Dahal LN, Huang CY, Stopforth RJ, Mead A, Chan K, Bowater JX, Taylor MC, Narang P, Chan HTC, Kim JH, Vaughan AT, Forconi F, Beers SA.

J Immunol. 2018 Aug 15;201(4):1211-1221. doi: 10.4049/jimmunol.1701122. Epub 2018 Jul 11.

PMID:
29997125
2.

Five years of ibrutinib in CLL.

Forconi F.

Blood. 2018 May 24;131(21):2280-2281. doi: 10.1182/blood-2018-03-837864. No abstract available.

PMID:
29794077
3.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

4.

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Maffei R, Fiorcari S, Martinelli S, Benatti S, Bulgarelli J, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.

PMID:
28639485
5.

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).

Haematologica. 2017 Jun;102(6):968-971. doi: 10.3324/haematol.2017.165605. No abstract available.

6.

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.

7.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

8.

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Drennan S, D'Avola A, Gao Y, Weigel C, Chrysostomou E, Steele AJ, Zenz T, Plass C, Johnson PW, Williams AP, Packham G, Stevenson FK, Oakes CC, Forconi F.

Leukemia. 2017 Aug;31(8):1686-1694. doi: 10.1038/leu.2016.356. Epub 2016 Nov 28.

PMID:
27890932
9.

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.

Carter MJ, Cox KL, Blakemore SJ, Turaj AH, Oldham RJ, Dahal LN, Tannheimer S, Forconi F, Packham G, Cragg MS.

Leukemia. 2017 Jun;31(6):1423-1433. doi: 10.1038/leu.2016.333. Epub 2016 Nov 15.

10.

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC.

Leukemia. 2016 Nov;30(11):2179-2186. doi: 10.1038/leu.2016.134. Epub 2016 May 20.

11.

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, Parnell J, Smith LD, Davies A, Johnson PWM, Conley PB, Pandey A, Strefford JC, Stevenson FK, Packham G, Forconi F, Coffey GP, Burger JA, Steele AJ.

Clin Cancer Res. 2017 May 1;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662. Epub 2016 Oct 3.

12.

PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.

Yeomans A, Lemm E, Wilmore S, Cavell BE, Valle-Argos B, Krysov S, Hidalgo MS, Leonard E, Willis AE, Forconi F, Stevenson FK, Steele AJ, Coldwell MJ, Packham G.

Oncotarget. 2016 Nov 15;7(46):74807-74819. doi: 10.18632/oncotarget.11655.

13.

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.

D'Avola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M, Rose-Zerilli M, Strefford J, Plass C, Johnson PW, Steele AJ, Packham G, Stevenson FK, Oakes CC, Forconi F.

Blood. 2016 Aug 11;128(6):816-26. doi: 10.1182/blood-2016-03-707786. Epub 2016 Jun 14.

14.

IL-4 enhances expression and function of surface IgM in CLL cells.

Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M, Smith LD, Linley A, Strefford JC, Davies A, Johnson PM, Savelyeva N, Cragg MS, Forconi F, Packham G, Stevenson FK, Steele AJ.

Blood. 2016 Jun 16;127(24):3015-25. doi: 10.1182/blood-2015-11-682906. Epub 2016 Mar 21.

15.

The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity.

Davis Z, Forconi F, Parker A, Gardiner A, Thomas P, Catovsky D, Rose-Zerilli M, Strefford JC, Oscier D.

Br J Haematol. 2016 Apr;173(1):127-36. doi: 10.1111/bjh.13940. Epub 2016 Feb 5.

PMID:
26846718
16.

Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.

Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, Leonard E, Ishfaq M, Wagner SD, Willis AE, Steele AJ, Stevenson FK, Forconi F, Coldwell MJ, Packham G.

Blood. 2016 Jan 28;127(4):449-57. doi: 10.1182/blood-2015-07-660969. Epub 2015 Oct 21.

17.

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.

Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJ, Walewska R, Duncombe A, Oscier D, Koide K, Forconi F, Packham G, Yoshida M, Cragg MS, Strefford JC, Steele AJ.

Leukemia. 2016 Feb;30(2):351-60. doi: 10.1038/leu.2015.286. Epub 2015 Oct 21.

PMID:
26488112
18.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

19.

Perturbation of the normal immune system in patients with CLL.

Forconi F, Moss P.

Blood. 2015 Jul 30;126(5):573-81. doi: 10.1182/blood-2015-03-567388. Epub 2015 Jun 17. Review.

20.

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.

Blunt MD, Carter MJ, Larrayoz M, Smith LD, Aguilar-Hernandez M, Cox KL, Tipton T, Reynolds M, Murphy S, Lemm E, Dias S, Duncombe A, Strefford JC, Johnson PW, Forconi F, Stevenson FK, Packham G, Cragg MS, Steele AJ.

Blood. 2015 Jun 25;125(26):4032-41. doi: 10.1182/blood-2014-11-610329. Epub 2015 May 8.

21.

Three years of ibrutinib in CLL.

Forconi F.

Blood. 2015 Apr 16;125(16):2455-6. doi: 10.1182/blood-2015-03-630772.

22.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC.

Clin Cancer Res. 2015 Sep 15;21(18):4174-4183. doi: 10.1158/1078-0432.CCR-14-2759. Epub 2015 Mar 16.

23.

Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia.

Linley A, Valle-Argos B, Steele AJ, Stevenson FK, Forconi F, Packham G.

Haematologica. 2015 Jul;100(7):e265-8. doi: 10.3324/haematol.2014.120824. Epub 2015 Mar 6. No abstract available.

24.

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F.

Blood. 2015 Mar 19;125(12):1922-31. doi: 10.1182/blood-2014-08-596247. Epub 2015 Jan 22.

25.

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.

Wang J, Khiabanian H, Rossi D, Fabbri G, Gattei V, Forconi F, Laurenti L, Marasca R, Del Poeta G, Foà R, Pasqualucci L, Gaidano G, Rabadan R.

Elife. 2014 Dec 11;3. doi: 10.7554/eLife.02869.

26.

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.

Pepper C, Buggins AG, Jones CH, Walsby EJ, Forconi F, Pratt G, Devereux S, Stevenson FK, Fegan C.

Leukemia. 2015 Mar;29(3):744-7. doi: 10.1038/leu.2014.308. Epub 2014 Oct 28. No abstract available.

27.

Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.

Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, Potter KN, Kennedy B, Duncombe AS, Ashton-Key M, Forconi F, Stevenson FK, Packham G.

Blood. 2014 Nov 13;124(20):3101-9. doi: 10.1182/blood-2014-04-567198. Epub 2014 Aug 28.

28.

The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.

Stevenson FK, Forconi F, Packham G.

Semin Hematol. 2014 Jul;51(3):158-67. doi: 10.1053/j.seminhematol.2014.05.003. Epub 2014 May 15. Review.

PMID:
25048780
29.

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Packham G, Krysov S, Allen A, Savelyeva N, Steele AJ, Forconi F, Stevenson FK.

Haematologica. 2014 Jul;99(7):1138-48. doi: 10.3324/haematol.2013.098384. Review.

30.

Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor.

Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V, Rossi D, Bonacorsi G, Zucchini P, Potenza L, Vallisa D, Gattei V, Del Poeta G, Forconi F, Gaidano G, Narni F, Luppi M, Marasca R.

PLoS One. 2014 Jun 5;9(6):e98818. doi: 10.1371/journal.pone.0098818. eCollection 2014.

31.

Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes.

Weston-Bell NJ, Forconi F, Kluin-Nelemans HC, Sahota SS.

PLoS One. 2014 Jan 30;9(1):e86556. doi: 10.1371/journal.pone.0086556. eCollection 2014.

32.

HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism.

Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S.

Haematologica. 2014 May;99(5):888-96. doi: 10.3324/haematol.2013.095281. Epub 2013 Dec 20.

33.

Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.

Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Exp Hematol. 2014 Feb;42(2):126-36.e1. doi: 10.1016/j.exphem.2013.10.007. Epub 2013 Nov 6.

PMID:
24212063
34.

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F.

Blood. 2013 Oct 10;122(15):2673-82. doi: 10.1182/blood-2013-03-489518. Epub 2013 Sep 4.

35.

Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.

Rinaldi A, Mensah AA, Kwee I, Forconi F, Orlandi EM, Lucioni M, Gattei V, Marasca R, Berger F, Cogliatti S, Cavalli F, Zucca E, Gaidano G, Rossi D, Bertoni F.

Br J Haematol. 2013 Oct;163(2):194-204. doi: 10.1111/bjh.12515. Epub 2013 Aug 21.

PMID:
23961875
36.

Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function.

Coelho V, Krysov S, Steele A, Sanchez Hidalgo M, Johnson PW, Chana PS, Packham G, Stevenson FK, Forconi F.

Blood. 2013 Oct 10;122(15):2664-72. doi: 10.1182/blood-2013-02-485425. Epub 2013 Aug 16.

37.

Genome-wide high resolution DNA profiling of hairy cell leukaemia.

Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F, Bertoni F.

Br J Haematol. 2013 Aug;162(4):566-9. doi: 10.1111/bjh.12393. Epub 2013 May 21. No abstract available.

PMID:
23692203
38.

Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.

Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V.

Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209. Epub 2013 May 1.

39.

Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH.

Mian M, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, Marasca R, Uhr M, Stussi G, Kwee I, Cavalli F, Gaidano G, Zucca E, Bertoni F.

Ann Oncol. 2013 May;24(5):1378-84. doi: 10.1093/annonc/mds646. Epub 2013 Jan 31.

PMID:
23372049
40.

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla-Favera R, Gaidano G.

Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.

41.

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.

De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, Martini M, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D.

Leuk Lymphoma. 2013 May;54(5):1087-90. doi: 10.3109/10428194.2012.723706. Epub 2012 Nov 12. No abstract available.

PMID:
23039309
42.

S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis.

Capitani N, Patrussi L, Trentin L, Lucherini OM, Cannizzaro E, Migliaccio E, Frezzato F, Gattazzo C, Forconi F, Pelicci P, Semenzato G, Baldari CT.

Blood. 2012 Nov 22;120(22):4391-9. doi: 10.1182/blood-2012-04-425959. Epub 2012 Oct 1.

43.

Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.

Marasca R, Maffei R, Martinelli S, Fiorcari S, Bulgarelli J, Debbia G, Rossi D, Rossi FM, Rigolin GM, Martinelli S, Gattei V, Del Poeta G, Laurenti L, Forconi F, Montillo M, Gaidano G, Luppi M.

Hematol Oncol. 2013 Jun;31(2):88-95. doi: 10.1002/hon.2028. Epub 2012 Oct 2. Erratum in: Hematol Oncol. 2013 Spe;31(3):168.

PMID:
23027683
44.

Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins.

Weston-Bell NJ, Hendriks D, Sugiyarto G, Bos NA, Kluin-Nelemans HC, Forconi F, Sahota SS.

Leukemia. 2013 Jan;27(1):241-5. doi: 10.1038/leu.2012.163. Epub 2012 Jun 18. No abstract available.

PMID:
22705994
45.

Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.

Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R, Cresta S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R, Larocca LM, Foà R, Gaidano G.

Br J Haematol. 2012 Aug;158(3):426-9. doi: 10.1111/j.1365-2141.2012.09155.x. Epub 2012 May 10. No abstract available.

PMID:
22571487
46.

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foà R, Gaidano G.

Blood. 2012 Mar 22;119(12):2854-62. doi: 10.1182/blood-2011-12-395673. Epub 2012 Feb 3.

47.

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.

Bulian P, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, D'Arena G, Efremov DG, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L.

J Transl Med. 2012 Jan 30;10:18. doi: 10.1186/1479-5876-10-18.

48.

The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells.

Forconi F, Potter KN, Sozzi E, Henderson I, Cencini E, Rossi D, Bomben R, Gattei V, Gaidano G, Packham G, Stevenson FK.

Blood. 2012 Mar 1;119(9):2106-9. doi: 10.1182/blood-2011-08-375501. Epub 2012 Jan 10.

49.

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, Ladetto M.

Haematologica. 2012 Jun;97(6):849-53. doi: 10.3324/haematol.2011.052852. Epub 2011 Dec 29.

50.

Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array.

Kwee I, Rinaldi A, Rancoita P, Rossi D, Capello D, Forconi F, Giuliani N, Piva R, Inghirami G, Gaidano G, Zucca E, Bertoni F.

Br J Haematol. 2012 Feb;156(3):354-7. doi: 10.1111/j.1365-2141.2011.08946.x. Epub 2011 Nov 25.

PMID:
22118580

Supplemental Content

Loading ...
Support Center